Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

减肥药“双雄”诺和诺德（NVO.US）和礼来（LLY.US），已先后公布了2025年6月财季业绩。在公布业绩之后，两家大型药企的股价均遭遇暴击。诺和诺德比礼来要早一天，其减肥药Wegovy（司美格鲁肽）于第2季度实现净销售收入195.28亿丹麦克朗， ...

DoNews8月13日消息，据财联社报道，礼来（LLY.N）于近日美股盘前公布了第二季度财报，营收与净利润均实现大幅增长。然而，其备受瞩目的实验性减肥药的最新临床数据不及预期，且逊色于竞争对手诺和诺德（NVO.N）的同作用药物，引发了市场对其能否保持竞争优势的担忧。

美国得克萨斯州总检察长肯·帕克斯顿周二对美国制药商礼来公司提起诉讼，指控其涉嫌"贿赂"医疗从业者开具该公司药物。总检察长办公室在声明中称，该公司通过贿赂和非法诱导手段促使医疗从业者开具其利润最高的药物，包括用于减肥和糖尿病治疗的GLP-1类药物蒙扎罗和Zepbound。帕克斯顿表示："大型制药公司通过非法回扣计划破 ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Investing.com -- 德州总检察长肯·帕克斯顿 (Ken Paxton)周二对礼来公司提起诉讼，指控这家美国制药商"贿赂"医疗服务提供者开具其药物处方。

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

在发布财报前，礼来还公布了其口服减重药Orforglipron的后期临床试验数据。其中最高剂量帮助患者平均减重逾12%。但这一结果未达市场预期，导致礼来股价在盘前交易中一度下跌多达12%。

Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.